Jefferies Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Jefferies Group’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-25,000	Closed	-$86K	–	2848
2017 Q1	$86K	Buy	+25,000	New	+$98.7K	﹤0.01%	2143
2015 Q1	–	Sell	-1,716	Closed	-$106K	–	2683
2014 Q4	$104K	Buy	+1,716	New	+$86.2K	﹤0.01%	1817
2014 Q2	–	Sell	-3,240	Closed	-$211K	–	2670
2014 Q1	$211K	Buy	3,240 +1,700	+110%	+$115K	﹤0.01%	1711
2013 Q4	$87K	Buy	+1,540	New	+$86.5K	﹤0.01%	1717
2013 Q3	–	Sell	-14	Closed	-$1K	–	2468
2013 Q2	$1K	Buy	+14	New	+$861	﹤0.01%	1827

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jefferies Group's OREX Position: Q2 2017 in Review

Jefferies Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2017, closing a stake of 25,000 shares — an estimated $86K sold.

Jefferies Group first reported a position in OREX in Q2 2013 and held it in 5 quarters. The position peaked at $211K in Q1 2014. 51 funds tracked by Wall St. Rank hold OREX as of Q2 2017.

Jefferies Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Jefferies Group sold 25,000 Orexigen Therapeutics, Inc. shares in Q2 2017, an estimated $86K.
Jefferies Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
Jefferies Group's Orexigen Therapeutics, Inc. position peaked at $211K in Q1 2014.
51 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2017.

Based on Jefferies Group's 13F filing for Q2 2017, filed 14 Aug 2017.